孟鲁司特钠对咳嗽变异性哮喘患者血清炎性因子、肺功能及临床效果的影响研究

Effect of montelukast sodium on serum inflammatory factors, lung function and clinical effect in patients with cough variant asthma

目的:探讨孟鲁司特钠对咳嗽变异性哮喘(CVA)患者血清炎性因子、肺功能及近远期临床效果的影响.方法:选取我院2016年4月-2018年6月130例CVA患者并随机分为对照组(65例)和观察组(65例);两组均给予吸氧、补液等常规治疗,对照组另给予沙丁胺醇气雾剂吸入治疗,观察组另给予沙丁胺醇气雾剂吸入联合孟鲁司特钠片口服治疗;采用酶联免疫吸附法检测两组血清炎性因子,采用肺功能检测仪检测两组肺功能;对比两组血清炎性因子水平、肺功能及临床效果.结果:治疗前,观察组血清IL6(28.32±8.14)pg/mL;对照组(28.16±8.04)pg/mL;观察组TNF-α(210.04±72.33)ng/mL,对照组(209.48±73.51)ng/mL水平无明显差异(P>0.05),治疗后,观察组血清IL6(14.15±2.03)pg/mL,对照组(20.57±3.18)pg/mL;观察组TNF-α(115.36±32.74)ng/mL,对照组(160.65±34.72)ng/mL均明显降低,且观察组降低程度明显高于对照组(P<0.05);治疗前,两组肺功能指标无明显差异,治疗后,两组肺功能指标均明显好转,且观察组好转程度均明显高于对照组(P<0.05);观察组(93.85%)治疗效果明显好于对照组(75.38%),差异具有统计学意义(P<0.05).结论:孟鲁司特钠在CVA治疗中能够降低CVA炎性因子水平,改善其肺功能指标,并提高患者治疗效果,值得在临床中应用.

Objective:To investigate the effects of montelukast sodium on serum inflammatory factors,lung function and short-term and long-term clinical effects in patients with cough variant asthma(CVA).Method:130 patients with CVA in our hospital from April 2016 to June 2018 were selected and randomly divided into the control group(65 cases)and the observation group(65 cases).Both groups were given routine treatment such as oxygen inhalation and fluid rehydration,the control group was given inhaled salbutamol aerosol,and the observation group was given oral treatment of salbutamol aerosol inhalation combined with montelukast sodium tablets.Two groups of serum in flammatory factors were detected by enzyme-linked immunosorbent assay,and lung function was detected by lung function detector.The levels of serum in flammatory factors,lung function and clinical e ffects were compared between the two groups.Results:Before treatment,there was no signi ficant di fference in serum IL6 in the two groups(28.32±8.14 pg/ml in the observation group,and 28.16±8.04 pg/ml in the control group)and TNF-α(210.04±72.33 ng/mL in the observation group,and 209.48±73.51ng/mL in the control group);After treatment,serum IL6(14.15±2.03 pg/ml in the observation group,20.57±3.18 pg/ml in the control group)and TNF-α(115.36±32.74 ng/mL in the observation group,160.65±34.72 ng/mL in the control group)were signi ficantly decreased in both groups.The degree of reduction in the observation group was significantly higher than that in the control group(P<0.05).Before treatment,there was no signi ficant difference in lung function indexes between the two groups.After treatment,lung function indexes in both groups improved signi ficantly,and the degree of improvement in the observation group was signi ficantly higher than that in the control group(P<0.05).The treatment e ffect of the observation group(93.85%)was signi ficantly better than that of the control group(75.38%),and the di fference was statistically signi ficant(P<0.05).Conclusion:Montelukast sodium can reduce the level of CVA in flammatory factors,improve its pulmonary function indicators,and improve the treatment effect of patients in the treatment of CVA,which is worthy of clinical application.